Home › Companies › Acadia Pharmaceuticals Inc. › 2025-2026

Acadia Pharmaceuticals Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Acadia Pharmaceuticals Inc.’s Form 8-K, filed May 29, 2026 (Item 5.07 on EDGAR). Page generated October 14, 2026.

6Reported items
376Asset managers
2,525Fund votes
May 29, 2026Meeting date

Results at a glance

Meeting of May 29, 2026: 5 items on Acadia Pharmaceuticals Inc.’s Form 8-K, filed May 29, 2026: 2 approved · 3 without a stated outcome.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Acadia Pharmaceuticals Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Acadia Pharmaceuticals Inc.

These tallies are Acadia Pharmaceuticals Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 29, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Acadia Pharmaceuticals Inc. — official shareholder meeting results, meeting held May 29, 2026
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: James M. Daly	146,927,745	--	--	3,521,002	10,356,394	98%	Not verified	—
Elect Director: Edmund P. Harrigan, M.D.	128,460,130	--	--	21,988,617	10,356,394	85%	Not verified	—
Elect Director: Adora Ndu, Pharm.D., J.D.	134,540,552	--	--	15,908,195	10,356,394	89%	Not verified	—
the approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, which was approved by the following vote	148,265,173	1,911,358	272,216	--	10,356,394	99%	Approved	—
the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, which was ratified by the following vote	157,409,378	3,319,736	76,027	--	--	98%	Approved	—

Source: Acadia Pharmaceuticals Inc., Form 8-K, filed with the SEC on May 29, 2026 — read the filing on EDGAR.

How asset managers voted at the Acadia Pharmaceuticals Inc. 2025-2026 meeting

Each item below shows how the 376 asset managers that disclosed a Acadia Pharmaceuticals Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Acadia Pharmaceuticals Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Elect Director: Adora Ndu, Pharm.D., J.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%

FOR: 134,540,552WITHHELD: 15,908,195

Details: description as filed, official tally, votes by 93 asset managers

Description as filed by funds: To elect the Board's three nominees for Class I director to hold office until the Company's 2029 Annual Meeting of Stockholders and their successors are duly elected and qualified, or until their earlier death, resignation or removal: Adora Ndu, Pharm.D., J.D.

Acadia Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Adora Ndu, Pharm.D., J.D.”): 134,540,552 for, 15,908,195 withheld, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 89% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 93 asset managers below reported 46,460,089 for, 6,831,662 withheld, 67 abstained, 88,571 not voted.

FOR

FOR: 46,460,089ABSTAIN: 67WITHHOLD: 6,831,662NOT VOTED: 88,571

Largest asset managers voting on “To elect the Board's three nominees for Class I director to hold office until the Company's 2029 Annual Meetin” at Acadia Pharmaceuticals Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
BlackRock	14,866,415	0	0	For
Vanguard	14,719,012	67	19,592	For
State Street	19,688	0	5,634,644	Withhold
Fidelity	3,475,543	0	0	For
First Trust	3,177,047	0	0	For
TIAA	1,141,112	0	0	For
Charles Schwab	1,051,680	0	0	For
Dimensional	1,000,882	0	0	For
MFS	621,810	0	0	For
Invesco	609,164	0	0	For
John Hancock	542,429	0	0	For
Columbia Threadneedle	537,427	0	0	For
Voya	445,735	0	0	For
ALGER FUNDS	426,213	0	0	For
T. Rowe Price	0	0	419,234	Withhold
Equitable	178,870	0	101,000	Mixed
Bridge Builder Trust	279,264	0	0	For
Jackson National	230,730	0	0	For
QUANTITATIVE MASTER SERIES LLC	203,782	0	0	For
HUSSMAN INVESTMENT TRUST	180,000	0	0	For
Prudential/PGIM	164,947	0	0	For
ALPS ETF Trust	162,935	0	0	For
Principal Exchange-Traded Funds	158,292	0	0	For
OLD WESTBURY FUNDS INC	149,600	0	0	For
Erste Asset Management GmbH	133,700	0	0	For

Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.

2. Elect Director: Edmund P. Harrigan, M.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 4 wordings of this item as funds reported it.

85% Majority: yes · of votes cast

FOR 85%WITHHELD

FOR: 128,460,130WITHHELD: 21,988,617

Details: description as filed, official tally, votes by 93 asset managers

Acadia Pharmaceuticals Inc.’s own tally for this item (“Elect Director: Edmund P. Harrigan, M.D.”): 128,460,130 for, 21,988,617 withheld, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 85% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 93 asset managers below reported 37,485,338 for, 15,646,380 withheld, 100 abstained, 88,571 not voted.

FORWITHHOLD

FOR: 37,485,338ABSTAIN: 100WITHHOLD: 15,646,380NOT VOTED: 88,571

Largest asset managers voting on “To elect the Board's three nominees for Class I director to hold office until the Company's 2029 Annual Meetin” at Acadia Pharmaceuticals Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
BlackRock	514,584	0	14,351,831	Withhold
Vanguard	14,702,586	100	35,985	For
State Street	5,646,482	0	7,850	For
Fidelity	3,421,607	0	53,936	For
First Trust	3,177,047	0	0	For
TIAA	1,141,112	0	0	For
Charles Schwab	1,051,680	0	0	For
Dimensional	1,000,882	0	0	For
MFS	621,810	0	0	For
Invesco	609,164	0	0	For
John Hancock	542,429	0	0	For
Columbia Threadneedle	537,427	0	0	For
Voya	445,735	0	0	For
ALGER FUNDS	426,213	0	0	For
T. Rowe Price	0	0	419,234	Withhold
Equitable	0	0	279,870	Withhold
Bridge Builder Trust	255,128	0	24,136	Mixed
Jackson National	230,730	0	0	For
QUANTITATIVE MASTER SERIES LLC	0	0	203,782	Withhold
Prudential/PGIM	164,947	0	0	For
ALPS ETF Trust	162,935	0	0	For
Principal Exchange-Traded Funds	158,292	0	0	For
OLD WESTBURY FUNDS INC	149,600	0	0	For
Erste Asset Management GmbH	133,700	0	0	For
Lincoln Financial	130,710	0	0	For

Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.

3. Elect Director: James M. Daly

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 146,927,745WITHHELD: 3,521,002

Details: description as filed, official tally, votes by 93 asset managers

Acadia Pharmaceuticals Inc.’s own tally for this item (“Elect Director: James M. Daly”): 146,927,745 for, 3,521,002 withheld, per its Form 8-K filed May 29, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 93 asset managers below reported 52,409,427 for, 722,375 withheld, 16 abstained, 88,571 not voted.

FOR

FOR: 52,409,427ABSTAIN: 16WITHHOLD: 722,375NOT VOTED: 88,571

Largest asset managers voting on “To elect the Board's three nominees for Class I director to hold office until the Company's 2029 Annual Meetin” at Acadia Pharmaceuticals Inc., 2025-2026
Asset manager	For	Abstain	Withheld	Vote
BlackRock	14,866,415	0	0	For
Vanguard	14,702,670	16	35,985	For
State Street	5,646,482	0	7,850	For
Fidelity	3,475,543	0	0	For
First Trust	3,177,047	0	0	For
TIAA	1,141,112	0	0	For
Charles Schwab	1,051,680	0	0	For
Dimensional	1,000,882	0	0	For
MFS	621,810	0	0	For
Invesco	609,164	0	0	For
John Hancock	542,429	0	0	For
Columbia Threadneedle	537,427	0	0	For
Voya	445,735	0	0	For
ALGER FUNDS	426,213	0	0	For
T. Rowe Price	0	0	419,234	Withhold
Equitable	178,870	0	101,000	Mixed
Bridge Builder Trust	279,264	0	0	For
Jackson National	230,730	0	0	For
QUANTITATIVE MASTER SERIES LLC	203,782	0	0	For
Prudential/PGIM	164,947	0	0	For
ALPS ETF Trust	162,935	0	0	For
Principal Exchange-Traded Funds	158,292	0	0	For
OLD WESTBURY FUNDS INC	149,600	0	0	For
Erste Asset Management GmbH	133,700	0	0	For
Lincoln Financial	130,710	0	0	For

Showing the 25 largest of 93 asset managers. See all 93 in the interactive database.

4. TO APPROVE AN AMENDMENT TO THE COMPANY'S 2024 EQUITY INCENTIVE PLAN TO, AMONG OTHER THINGS, INCREASE THE AGGREGATE…

No official matchCOMPENSATION

99.2% of fund votes cast · no official result

FOR

Details: description as filed, votes by 92 asset managers

Description as filed by funds: TO APPROVE AN AMENDMENT TO THE COMPANY'S 2024 EQUITY INCENTIVE PLAN TO, AMONG OTHER THINGS, INCREASE THE AGGREGATE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THE PLAN BY 5,209,670 SHARES.

The 92 asset managers below reported 52,713,939 for, 405,344 against, 16,375 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 52,713,939AGAINST: 405,344ABSTAIN: 16,375

Largest asset managers voting on “TO APPROVE AN AMENDMENT TO THE COMPANY'S 2024 EQUITY INCENTIVE PLAN TO, AMONG OTHER THINGS, INCREASE THE AGGRE” at Acadia Pharmaceuticals Inc., 2025-2026
Asset manager	For	Against	Vote
BlackRock	14,866,415	0	For
Vanguard	14,702,637	36,034	For
State Street	5,646,194	8,138	For
Fidelity	3,475,543	0	For
First Trust	3,177,047	0	For
TIAA	1,141,112	0	For
Charles Schwab	1,051,680	0	For
Dimensional	1,000,882	0	For
MFS	621,810	0	For
Invesco	609,164	0	For
John Hancock	542,429	0	For
Columbia Threadneedle	537,427	0	For
Voya	445,735	0	For
ALGER FUNDS	426,213	0	For
T. Rowe Price	419,234	0	For
Equitable	279,870	0	For
Bridge Builder Trust	279,264	0	For
Jackson National	230,730	0	For
QUANTITATIVE MASTER SERIES LLC	203,782	0	For
HUSSMAN INVESTMENT TRUST	0	180,000	Against
Prudential/PGIM	164,947	0	For
ALPS ETF Trust	162,935	0	For
Principal Exchange-Traded Funds	158,292	0	For
OLD WESTBURY FUNDS INC	149,600	0	For
Lincoln Financial	130,710	0	For

Showing the 25 largest of 92 asset managers. See all 92 in the interactive database.

5. the approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in the…

Official result Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 14 wordings of this item as funds reported it.

99% Approved · of votes cast

FOR 99%

FOR: 148,265,173AGAINST: 1,911,358

Details: description as filed, official tally, votes by 375 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.

Acadia Pharmaceuticals Inc.’s own tally for this item (“the approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, which was approved by the following vote”): 148,265,173 for, 1,911,358 against — passed, per its Form 8-K filed May 29, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “In addition to the election of three Class I directors, the following matters were submitted to a vote of the stockholders at the Annual Meeting: (i) the approval, on an advisory basis, of the compensation of the Company's named executive officers, as disclosed in the Proxy Statement, which was app…”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 91 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at Acadia Pharmaceuticals Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
BlackRock	14,866,415	0	0	For
Vanguard	14,738,663	7	1	For
State Street	5,654,332	0	0	For
Fidelity	3,475,543	0	0	For
First Trust	3,177,047	0	0	For
TIAA	1,141,112	0	0	For
Charles Schwab	1,051,680	0	0	For
Dimensional	1,000,882	0	0	For
MFS	621,810	0	0	For
Invesco	609,164	0	0	For
John Hancock	542,429	0	0	For
Columbia Threadneedle	537,427	0	0	For
Voya	445,735	0	0	For
ALGER FUNDS	426,213	0	0	For
T. Rowe Price	419,234	0	0	For
Equitable	279,870	0	0	For
Bridge Builder Trust	279,264	0	0	For
RBB FUND, INC.	253,402	0	0	For
Jackson National	230,730	0	0	For
QUANTITATIVE MASTER SERIES LLC	203,782	0	0	For
HUSSMAN INVESTMENT TRUST	0	0	180,000	Abstain
Prudential/PGIM	164,947	0	0	For
ALPS ETF Trust	162,935	0	0	For
Principal Exchange-Traded Funds	158,292	0	0	For
OLD WESTBURY FUNDS INC	149,600	0	0	For

Fund voting reports, all 91 managers: 53,107,488 for, 90,323 against, 196,376 abstained, 88,571 not voted. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 306 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at Acadia Pharmaceuticals Inc., 2025-2026
Asset manager	For	Against	Vote
BAKER BROS. ADVISORS LP	43,102,442	0	For
RTW INVESTMENTS, LP	7,144,524	0	For
BlackRock	4,926,437	2,134	For
GEODE CAPITAL MANAGEMENT, LLC	3,466,247	0	For
Palo Alto Investors LP	2,864,096	0	For
State Street	2,453,769	4,276	For
Point72	1,975,507	0	For
PICTET ASSET MANAGEMENT SA	1,839,632	0	For
Frazier Life Sciences Management, L.P.	1,438,198	0	For
Charles Schwab	1,196,083	0	For
Nuveen	1,163,143	0	For
Artisan	1,156,870	0	For
Logos Global Management LP	1,147,084	0	For
Northern Trust	1,110,186	0	For
Vanguard	1,076,129	0	For
WEATHERBIE CAPITAL, LLC	1,005,974	0	For
Allspring	990,027	0	For
BRAIDWELL LP	935,406	0	For
ROCKEFELLER FINANCIAL LLC	906,755	0	For
MASSACHUSETTS FINANCIAL SERVICES CO /MA/	897,318	0	For
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP	839,951	0	For
T. Rowe Price	834,569	0	For
Renaissance	811,095	0	For
PRINCIPAL GLOBAL INVESTORS	769,882	0	For
MELLON INVESTMENTS Corp	745,614	0	For

Institutional-manager reports, all 306 managers: 98,514,899 for, 1,228,633 against, 6,083 not voted. Showing the 25 largest; see all in the interactive database.

6. the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%

FOR: 157,409,378AGAINST: 3,319,736

Details: description as filed, official tally, votes by 94 asset managers

Description as filed by funds: TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

Acadia Pharmaceuticals Inc.’s own tally for this item (“the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, which was ratified by the following vote”): 157,409,378 for, 3,319,736 against — passed, per its Form 8-K filed May 29, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “(ii) the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, which was ratified by the following vote:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 94 asset managers below reported 52,791,261 for, 496,232 against, 16,375 abstained, 88,571 not voted.

FOR

FOR: 52,791,261AGAINST: 496,232ABSTAIN: 16,375NOT VOTED: 88,571

Largest asset managers voting on “TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FO” at Acadia Pharmaceuticals Inc., 2025-2026
Asset manager	For	Against	Vote
BlackRock	14,866,415	0	For
Vanguard	14,738,657	14	For
State Street	5,651,683	2,649	For
Fidelity	3,475,543	0	For
First Trust	3,177,047	0	For
TIAA	1,141,112	0	For
Charles Schwab	1,051,680	0	For
Dimensional	1,000,882	0	For
MFS	621,810	0	For
Invesco	609,164	0	For
John Hancock	542,429	0	For
Columbia Threadneedle	537,427	0	For
Voya	445,735	0	For
ALGER FUNDS	0	426,213	Against
T. Rowe Price	419,234	0	For
Equitable	279,870	0	For
Bridge Builder Trust	279,264	0	For
Jackson National	230,730	0	For
QUANTITATIVE MASTER SERIES LLC	203,782	0	For
HUSSMAN INVESTMENT TRUST	180,000	0	For
Prudential/PGIM	164,947	0	For
ALPS ETF Trust	162,935	0	For
Principal Exchange-Traded Funds	158,292	0	For
OLD WESTBURY FUNDS INC	149,600	0	For
Erste Asset Management GmbH	133,700	0	For

Showing the 25 largest of 94 asset managers. See all 94 in the interactive database.

Largest Acadia Pharmaceuticals Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 171,086,205 shares outstanding at the time of that meeting.

Fund voting reports: top Acadia Pharmaceuticals Inc. shareholders by shares voted on “TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC…”, 2025-2026
#	Asset manager	% of shares outstanding
1	BlackRock	8.69%
2	Vanguard	8.61%
3	State Street	3.30%
4	Fidelity	2.03%
5	First Trust	1.86%
6	TIAA	0.67%
7	Charles Schwab	0.61%
8	Dimensional	0.59%
9	MFS	0.36%
10	Invesco	0.36%

Institutional-manager reports: top Acadia Pharmaceuticals Inc. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's named executive officers…”, 2025-2026
#	Asset manager	% of shares outstanding
1	BAKER BROS. ADVISORS LP	25.19%
2	RTW INVESTMENTS, LP	4.18%
3	BlackRock	2.88%
4	GEODE CAPITAL MANAGEMENT, LLC	2.03%
5	Palo Alto Investors LP	1.67%
6	State Street	1.44%
7	Point72	1.15%
8	PICTET ASSET MANAGEMENT SA	1.08%
9	Frazier Life Sciences Management, L.P.	0.84%
10	Charles Schwab	0.70%

Reported Acadia Pharmaceuticals Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

Acadia Pharmaceuticals Inc. holdings and ownership disclosed for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Baker Bros. Advisors LP	25.34%	DEF14A
Julian C. Baker	25.34%	DEF14A
Stephen R. Biggar	25.28%	DEF14A
BlackRock	12.60%	13F
Vanguard Group	8.86%	13F
State Street	4.87%	13F
Geode Capital	2.03%	13F
Dimensional Fund Advisors	1.84%	13F
Point72	1.52%	13F
Renaissance Technologies	1.01%	13F

Percentages above are of 171,086,205 shares outstanding, as reported by Acadia Pharmaceuticals Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Acadia Pharmaceuticals Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.

At Acadia Pharmaceuticals Inc.'s shareholder meeting held May 29, 2026, in the 2025-2026 proxy season, 376 asset managers reported how they voted in their SEC Form N-PX filings, covering 2,525 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers… — Acadia Pharmaceuticals Inc.'s filing reports the proposal as approved, with 99% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Acadia Pharmaceuticals Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 29, 2026.

Acadia Pharmaceuticals Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Download data (CSV): ballot items · votes by manager · column guide.